| Document and Entity Information | 6 Months Ended |
| Jun. 30, 2023 | |
| Cover [Abstract] | |
| Entity Registrant Name | MediWound Ltd. |
| Entity Central Index Key | 0001593984 |
| Document Type | 6-K |
| Document Period End Date | Jun. 30, 2023 |
| Amendment Flag | false |
| Current Fiscal Year End Date | --12-31 |
| Document Fiscal Period Focus | Q2 |
| Document Fiscal Year Focus | 2023 |
| Entity File Number | 001-36349 |
| Entity Address, Address Line One | 42 Hayarkon Street |
| Entity Address, City or Town | Yavne |
| Entity Address, Postal Zip Code | 8122745 |
| Entity Address, Country | IL |
| Unaudited Condensed Interim Consolidated Statements of Financial Position - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 | Jun. 30, 2022 |
| CURRENT ASSETS: | |||
| Cash and cash equivalents | $ 19,166 | $ 33,895 | $ 7,729 |
| Restricted deposits | 0 | 0 | 168 |
| Short-term bank deposits | 31,956 | 0 | 2,509 |
| Trade receivables | 3,228 | 9,332 | 3,759 |
| Inventories | 3,113 | 1,963 | 1,991 |
| Other receivables | 590 | 650 | 653 |
| Total current assets | 58,053 | 45,840 | 16,809 |
| LONG-TERM ASSETS: | |||
| Other receivables | 277 | 364 | 230 |
| Property, plant and equipment, net | 4,705 | 2,366 | 2,439 |
| Right of-use assets, net | 1,133 | 1,215 | 1,364 |
| Intangible assets, net | 198 | 231 | 264 |
| Total non-current assets | 6,313 | 4,176 | 4,297 |
| Total assets | 64,366 | 50,016 | 21,106 |
| CURRENT LIABILITIES: | |||
| Current maturities of non-current liabilities | 1,961 | 2,242 | 2,479 |
| Trade payables and accrued expenses | 3,531 | 5,656 | 4,877 |
| Other payables | 2,817 | 4,159 | 3,060 |
| Total current liabilities | 8,309 | 12,057 | 10,416 |
| LONG-TERM LIABILITIES: | |||
| Deferred revenues | 0 | 0 | 61 |
| Warrants | 9,683 | 15,606 | 0 |
| Liabilities in respect of IIA grants | 7,806 | 7,445 | 8,131 |
| Liabilities in respect of TEVA | 2,529 | 2,788 | 3,361 |
| Lease liabilities | 677 | 846 | 1,053 |
| Severance pay liability, net | 433 | 360 | 319 |
| Total non-current liabilities | 21,128 | 27,045 | 12,925 |
| Total liabilities | 29,437 | 39,102 | 23,341 |
| Shareholders' equity: | |||
| Ordinary shares of NIS 0.01 par value: Authorized: 20,000,000 shares as of June 30, 2023, 12,857,143 as of December 31, 2022; and 7,142,858 as of June 30, 2022; Issued and Outstanding: 7,252,234 as of June 30, 2023; 7,240,020 as of December 31, 2022 and 4,734,774 as of June 30, 2022 | 184 | 143 | 93 |
| Share premium | 205,642 | 178,882 | 154,119 |
| Foreign currency translation adjustments | (14) | (5) | 3 |
| Accumulated deficit | (170,883) | (168,106) | (156,450) |
| Total equity (deficit) | 34,929 | 10,914 | (2,235) |
| Total liabilities and equity | $ 64,366 | $ 50,016 | $ 21,106 |
| Unaudited Condensed Interim Consolidated Statements of Financial Position (Parenthetical) - ₪ / shares | Jun. 30, 2023 | Dec. 31, 2022 | Jun. 30, 2022 |
| Statement of financial position [abstract] | |||
| Ordinary shares, par value (per share) | ₪ 0.01 | ₪ 0.01 | ₪ 0.01 |
| Number of shares authorised | 20,000,000 | 12,857,143 | 7,142,858 |
| Number of shares issued | 7,252,234 | 7,240,020 | 4,734,774 |
| Ordinary shares, Outstanding | 7,252,234 | 7,240,020 | 4,734,774 |
| Unaudited Condensed Interim Consolidated Statements of Profit or Loss and Other Comprehensive Income or Loss - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||||
| Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | Dec. 31, 2022 | |||
| Profit or loss [abstract] | |||||||
| Revenues from sale of products | $ 1,206 | $ 1,669 | $ 2,358 | $ 2,771 | $ 5,347 | ||
| Revenues from development services | 3,534 | 2,777 | 6,149 | 5,866 | 12,943 | ||
| Revenues from license agreements | 33 | 222 | 65 | 438 | 8,206 | ||
| Total revenues | 4,773 | 4,668 | 8,572 | 9,075 | 26,496 | ||
| Cost of revenues from sale of products | 628 | 1,148 | 1,436 | 1,539 | 3,184 | ||
| Cost of revenues from development services | 3,005 | 2,391 | 5,170 | 4,932 | 9,829 | ||
| Cost of revenues from license agreements | 3 | 16 | 3 | 31 | 318 | ||
| Total cost of revenues | 3,636 | 3,555 | 6,609 | 6,502 | 13,331 | ||
| Gross profit | 1,137 | 1,113 | 1,963 | 2,573 | 13,165 | ||
| Research and development | 2,024 | 2,191 | 4,126 | 4,599 | 10,181 | ||
| Selling and marketing | 1,332 | 935 | 2,438 | 1,854 | 3,725 | ||
| General and administrative | 1,788 | 1,352 | 3,770 | 2,769 | 6,920 | ||
| Other expenses | 0 | 309 | 0 | 309 | 684 | ||
| Total operating expenses | 5,144 | 4,787 | 10,334 | 9,531 | 21,510 | ||
| Operating loss | (4,007) | (3,674) | (8,371) | (6,958) | (8,345) | ||
| Financial income | 5,828 | 11 | 7,480 | 11 | 461 | ||
| Financial expenses | (893) | (687) | (1,869) | (988) | (11,637) | ||
| Financing income (expenses), net | 4,935 | (676) | 5,611 | (977) | (11,176) | ||
| Profit (loss) before taxes on income | 928 | (4,350) | (2,760) | (7,935) | (19,521) | ||
| Taxes on income | (12) | (4) | (17) | (8) | (78) | ||
| Net profit (loss) | 916 | (4,354) | (2,777) | (7,943) | (19,599) | ||
| Other comprehensive income: | |||||||
| Foreign currency translation adjustments | 0 | 17 | (9) | 22 | 14 | ||
| Total comprehensive profit (loss) | $ 916 | $ (4,337) | $ (2,786) | $ (7,921) | $ (19,585) | ||
| Loss per share data: | |||||||
| Basic net profit (loss) per share | $ 0.1 | $ (0.92) | [1] | $ (0.32) | $ (1.79) | [1] | $ (3.93) |
| Diluted net profit (loss) per share | $ 0.1 | $ (0.92) | $ (0.32) | $ (1.79) | $ (3.93) | ||
| Number of shares used in calculating basic net loss per share | 9,209 | 4,734 | [1] | 8,803 | 4,440 | [1] | 4,987 |
| Number of shares used in calculating diluted net loss per share | 9,209 | 4,734 | 8,803 | 4,440 | 4,987 | ||
| [1]Restated to reflect 1:7 reverse ratio of shares | |||||||
| Unaudited Condensed Interim Consolidated Statements of Changes in Shareholders' Equity (Deficit) - USD ($) $ in Thousands | Share capital [Member] | Share premium [Member] | Foreign currency translation reserve [Member] | Accumulated deficit [Member] | Total | |||
| Balance at Dec. 31, 2021 | $ 75 | $ 143,869 | $ (19) | $ (148,507) | $ (4,582) | |||
| Profit (loss) for the period | 0 | 0 | 0 | (7,943) | (7,943) | |||
| Other comprehensive income (loss) | 0 | 0 | 22 | 0 | 22 | |||
| Total comprehensive income (loss) | 0 | 0 | 22 | (7,943) | (7,921) | |||
| Issuance of ordinary shares, net of issuance expenses | 18 | 9,653 | 0 | 0 | 9,671 | |||
| Exercise of options | [1] | 0 | 0 | 0 | [1] | |||
| Share-based compensation | 0 | 597 | 0 | 0 | 597 | |||
| Balance at Jun. 30, 2022 | 93 | 154,119 | 3 | (156,450) | (2,235) | |||
| Balance at Dec. 31, 2021 | 75 | 143,869 | (19) | (148,507) | (4,582) | |||
| Profit (loss) for the period | 0 | 0 | 0 | (19,599) | (19,599) | |||
| Other comprehensive income (loss) | 0 | 0 | 14 | 0 | 14 | |||
| Total comprehensive income (loss) | 0 | 14 | (19,599) | (19,585) | ||||
| Issuance of ordinary shares, net of issuance expenses | 40 | 17,389 | 0 | 0 | 17,429 | |||
| Exercise of options | [1] | [1] | 0 | 0 | [1] | |||
| Exercise of pre-funded warrants | 28 | 15,678 | 0 | 0 | 15,706 | |||
| Share-based compensation | 0 | 1,946 | 0 | 0 | 1,946 | |||
| Balance at Dec. 31, 2022 | 143 | 178,882 | (5) | (168,106) | 10,914 | |||
| Balance at Mar. 31, 2022 | 93 | 153,962 | (14) | (152,096) | 1,945 | |||
| Profit (loss) for the period | 0 | 0 | 0 | (4,354) | (4,354) | |||
| Other comprehensive income (loss) | 0 | 0 | 17 | 0 | 17 | |||
| Total comprehensive income (loss) | 0 | 0 | 17 | (4,354) | (4,337) | |||
| Issuance expenses | 0 | (95) | 0 | 0 | (95) | |||
| Exercise of options | [1] | 0 | 0 | 0 | [1] | |||
| Share-based compensation | 0 | 252 | 0 | 0 | 252 | |||
| Balance at Jun. 30, 2022 | 93 | 154,119 | 3 | (156,450) | (2,235) | |||
| Balance at Dec. 31, 2022 | 143 | 178,882 | (5) | (168,106) | 10,914 | |||
| Profit (loss) for the period | 0 | 0 | 0 | (2,777) | (2,777) | |||
| Other comprehensive income (loss) | 0 | 0 | (9) | 0 | (9) | |||
| Total comprehensive income (loss) | 0 | 0 | (9) | (2,777) | (2,786) | |||
| Issuance of ordinary shares, net of issuance expenses | 40 | 25,429 | 0 | 0 | 25,469 | |||
| Exercise of options | 1 | 0 | 0 | 0 | 1 | |||
| Share-based compensation | 0 | 1,331 | 0 | 0 | 1,331 | |||
| Balance at Jun. 30, 2023 | 184 | 205,642 | (14) | (170,883) | 34,929 | |||
| Balance at Mar. 31, 2023 | 183 | 204,930 | (14) | (171,799) | 33,300 | |||
| Profit (loss) for the period | 0 | 0 | 0 | 916 | 916 | |||
| Other comprehensive income (loss) | 0 | 0 | 0 | 0 | 0 | |||
| Total comprehensive income (loss) | 0 | 0 | 0 | 916 | 916 | |||
| Issuance expenses | 0 | 0 | 0 | 0 | 0 | |||
| Exercise of options | 1 | 0 | 0 | 0 | 1 | |||
| Share-based compensation | 0 | 712 | 0 | 0 | 712 | |||
| Balance at Jun. 30, 2023 | $ 184 | $ 205,642 | $ (14) | $ (170,883) | $ 34,929 | |||
| [1]Represents less than $ 1. | ||||||||
| Unaudited Condensed Interim Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||
| Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | Dec. 31, 2022 | |
| Cash flows from operating activities: | |||||
| Net income (loss) | $ 916 | $ (4,354) | $ (2,777) | $ (7,943) | $ (19,599) |
| Adjustments to profit and loss items: | |||||
| Depreciation and amortization | 315 | 329 | 618 | 650 | 1,272 |
| Share-based compensation | 712 | 252 | 1,331 | 597 | 1,946 |
| Revaluation of warrants accounted at fair value | (4,990) | 0 | (5,923) | 0 | 8,977 |
| Issuance expenses of warrants through profit and loss | 0 | 0 | 0 | 0 | 1,911 |
| Revaluation of liabilities in respect of IIA grants | 233 | 248 | 492 | 482 | (132) |
| Revaluation of liabilities in respect of TEVA | 119 | 135 | 241 | 272 | 533 |
| Revaluation of lease liabilities | (9) | (138) | (22) | (152) | (109) |
| Increase (decrease) in severance pay liability, net | (10) | 35 | 67 | 55 | 109 |
| Net financing income | (759) | (11) | (1,005) | (11) | (74) |
| Un-realized foreign currency loss | 120 | 283 | 466 | 528 | 525 |
| Adjustments to profit and loss items, total | (4,269) | 1,133 | (3,735) | 2,421 | 14,958 |
| Changes in asset and liability items: | |||||
| Decrease (increase) in trade receivables | (707) | (1,445) | 6,115 | (2,024) | (7,582) |
| Increase in inventories | (579) | (37) | (1,162) | (747) | (721) |
| Decrease in other receivables | 435 | 205 | 122 | 330 | 364 |
| Increase (decrease) in trade payables and accrued expenses | 312 | (272) | (1,636) | 11 | 414 |
| Increase (decrease) in other payables and deferred revenues | (1,359) | (484) | (1,526) | (1,367) | 281 |
| Changes in asset and liability items, total | (1,898) | (2,033) | 1,913 | (3,797) | (7,244) |
| Net cash (used in) operating activities | (5,251) | (5,254) | (4,599) | (9,319) | (11,885) |
| Cash Flows from Investing Activities: | |||||
| Purchase of property and equipment | (1,065) | (138) | (2,570) | (298) | (555) |
| Interest received | 577 | 0 | 879 | 0 | 74 |
| Investment in short term bank deposits, net | (25,590) | (2,499) | (31,830) | (2,499) | 0 |
| Net cash used in investing activities | (26,078) | (2,637) | (33,521) | (2,797) | (481) |
| Cash Flows from Financing Activities: | |||||
| Repayment of leases liabilities | (157) | (172) | (334) | (350) | (701) |
| Proceeds from exercise of options | |||||
| Proceeds from exercise of pre-funded warrants | 0 | 0 | 0 | 0 | 10 |
| Proceeds from (Repayment of) issuance of shares and warrants, net | (248) | (556) | 24,909 | 9,861 | 38,380 |
| Repayment of IIA grants, net | 0 | 0 | (310) | (162) | (258) |
| Repayment of liabilities in respect of TEVA | 0 | 0 | (417) | 0 | (1,667) |
| Net cash provided by (used in) financing activities | (405) | (728) | 23,848 | 9,349 | 35,764 |
| Exchange rate differences on cash and cash equivalent balances | (120) | (303) | (457) | (550) | (549) |
| Increase (decrease) in cash and cash equivalents | (31,854) | (8,922) | (14,729) | (3,317) | 22,849 |
| Balance of cash and cash equivalents at the beginning of the period | 51,020 | 16,651 | 33,895 | 11,046 | 11,046 |
| Balance of cash and cash equivalents at the end of the period | 19,166 | 7,729 | 19,166 | 7,729 | 33,895 |
| Supplement disclosure of Non-cash transactions: | |||||
| ROU asset, net recognized with corresponding lease liability | $ 102 | $ 43 | $ 154 | $ 43 | $ 117 |
| General | 6 Months Ended |
| Jun. 30, 2023 | |
| Disclosure Of General Information [Abstract] | |
| General | Note 1: General a. Description of the Company and its operations: MediWound Ltd. Was incorporated in Israel. The Company which is located in Yavne, Israel (The "Company" or "MediWound"), is biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic, non-surgical solutions for tissue repair and regeneration. The Company’s strategy leverages its breakthrough enzymatic technology platform into diversified portfolio of biotherapeutics across multiple indications to pioneer solutions for unmet medical needs. The Company's first innovative biopharmaceutical product, NexoBrid, has received in December 2022, an approval from the U.S. Food and Drug Administration (“FDA”) and marketing approval in each of India, Switzerland and Japan. In addition it has a marketing authorization from the European Medicines Agency (“EMA”) and regulatory agencies in other international markets for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full thickness thermal burns. The Company commercialize NexoBrid globally through multiple sales channels. • The Company sell NexoBrid to burn centers in the European Union, United Kingdom and Israel, primarily through its commercial organizations. • The Company have established local distribution channels in multiple international markets, focusing on Asia Pacific, EMEA, CEE and LATAM, which local distributors are also responsible for obtaining local marketing authorization within the relevant territories. • In the United States, the Company entered into exclusive license and supply agreements with Vericel Corporation (“Vericel”) to commercialize NexoBrid in North America upon FDA approval. The Company’s second investigational next-generation enzymatic therapy product, EscharEx, a topical biological drug being developed for debridement of chronic and other hard-to-heal wounds, is currently under discussions with the FDA regarding the pivotal Phase 3 study design. The third clinical-stage innovative product candidate, MW005, is a topical applied biological drug candidate for the treatment of non-melanoma skin cancers. A U.S. phase 1/2 study of MW005 for the treatment of low-risk basal cell carcinoma (BCC) was initiated in July 2021, and an investigator-initiated phase II trial of MW005 in non-melanoma skin cancer is being conducted in parallel in Israel. In December 2022, the Company announced final positive results from the study. Based on the positive results, The Company plan to continue enrolling patients in its Phase 1/2 study. b. The Company's securities are listed for trading on NASDAQ since March 2014. c. The Company has three wholly owned subsidiaries: MediWound Germany GmbH, acting as Europe (“EU”) marketing authorization holder and EU sales and marketing arm, and MediWound UK Limited and MediWound US, Inc. which are currently inactive companies. d. The Company awarded two contracts with the U.S. Biomedical Advanced Research and Development Authority ("BARDA") valued at up to $209,000 for the advancement of the development, manufacturing and emergency readiness for NexoBrid deployment as well as the procurement of NexoBrid as a medical countermeasure as part of BARDA preparedness for mass casualty events. On May 9, 2023 BARDA has awarded an additional $10,000 to the Company. The supplemental funding will support $7,000 R&D activities and $3,000 replenishment of expired product previously procured for emergency preparedness, the pediatric indication sBLA submission to the U.S. Food and Drug Administration (FDA), and enrollment of an additional 50 patients in the ongoing expanded access treatment protocol (NEXT). e. Our Partner, Vericel Corporation Inc. (“ Vericel f. In 2022 the Company engaged with the U.S. Department of Defense (DoD), through the Medical Technology Enterprise Consortium (MTEC), for a $1,800 contract for the development of NexoBrid as a non-surgical solution for field-care burn treatment for the U.S. Army. This contract was amended in April 2023 to extend the total value, up to a total amount of $2,700. |
| Significant Accounting Policies | 6 Months Ended |
| Jun. 30, 2023 | |
| Disclosure of significant accounting policies [Abstract] | |
| Significant Accounting Policies | Note 2: S ignificant Accounting Policies The following accounting policies have been applied consistently in the financial statements for all periods presented unless otherwise stated. a. Basis of presentation of financial statements: These financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). b. Basis of preparation of the interim consolidated financial statements: The interim condensed consolidated financial statements for the six and three months ended June 30, 2023 have been prepared in accordance with IAS 34 "Interim Financial Reporting". The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Company's annual financial statements as of December 31, 2022 that were included in the Annual Report on Form 20-F filed on March 16, 2023. The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Company’s annual consolidated financial statements for the year ended December 31, 2022 that were included in the Annual Report on Form 20-F filed on March 16, 2023. |
| Equity | 6 Months Ended |
| Jun. 30, 2023 | |
| SHAREHOLDERS' EQUITY: | |
| Equity | Note 3: Equity 1. On February 7, 2023, the Company completed a public offering of 1,964,286 new ordinary shares which were issued in consideration to offering price of $14.0 per share. The gross proceeds were $27,500, before deducting commissions and other offering expenses in the amount of $2,031. 2. On February 15, 2023, the Company granted to its employees and officers 130,600 share options for an exercise price of $13.32 per share and 9,100 RSUs. The share options vest over a period of 4 years. The total value was estimated at $1,129. 3. On April 3, 2023, the Company granted to its board members and officers 160,400 share options for an exercise price of $11.89 and $11.91 per share. The grants to the directors and CEO were subject to the approval of the shareholders’ meeting held on May, 2023. The share options vest over a period of 1-4 years and the total value was estimated at $884. 4. On May 31, 2023 the Shareholders of the Company approved an amendment to Article 6 of the Company’s Amended and Restated Articles of Association, which increased the Company’s authorized share capital from 900,000 NIS consisting of 12,857,143 ordinary shares par value NIS 0.07 to NIS 1,400,000, consisting of 20,000,000 ordinary shares, par value NIS 0.07 per share. 5. On May 31, 2023 the Shareholders of the Company approved the increase by 1,000,000 in the number of ordinary shares available for issuance under the Company’s 2014 Equity Incentive Plan. 6. On May 31, 2023 the Shareholders of the Company approved the extension to the exercise period of options which were granted to the company’s directors on April 23, 2020 for an additional five years, until April 23, 2030. According to this extension, an expense of $146 was recognized. |
| Subsequent events | 6 Months Ended |
| Jun. 30, 2023 | |
| Disclosure of non-adjusting events after reporting period [abstract] | |
| Subsequent events | Note 4: Subsequent events 1. On July 17, 2023 the company signed a turnkey scale-up agreement with Biopharmax Group Ltd. This strategic agreement is designed to bolster the company’s manufacturing infrastructure to support our long-term growth trajectory. The objective of this agreement is to establish, commission, and validate a cutting-edge, sterile, and GMP-compliant manufacturing facility. The venture aims to increase our production capacity significantly, projected to expand to six times the current capacity, aligning with our strategic plan to meet the escalating global demand for NexoBrid. The new facility, equipped with fully operational clean rooms, will be exclusively designed for NexoBrid production. It will comply with stringent regulations from the GMP, FDA, EMA, Israeli Ministry of Health, and relevant Israeli regulatory bodies. An estimated $12,000 will be invested in the project, set for completion by mid-2024, with full-scale manufacturing expected to commence in 2025. The Scale-up Agreement encompasses various standard provisions, including those related to reporting, compliance, guarantees, representations, liability, insurance, confidentiality, and ownership. 2. Alongside entering the Scale-up Agreement, the company has also secured a new lease agreement with the current property owner. This agreement allows the company to continue the utilization of our existing facilities and the planned manufacturing site. This property, located in Yavne, Israel, serves as the base for the company’s administrative headquarters, research and development laboratories, and manufacturing plant. The duration of the lease extends until 2035, with an option for a further three-year extension until 2038. In parallel the existing sub lease agreement with Clal Life Science L.P. and the company was terminated. The property, measuring approximately 32,500 square feet, will encompass the new manufacturing facility. As per the Lease Agreement, the annual rent is set at approximately $625. This rent is indexed to the Israeli Consumer Price Index and will see a staged increase of 6% every three years. |
| Significant Accounting Policies (Policies) | 6 Months Ended |
| Jun. 30, 2023 | |
| Disclosure of significant accounting policies [Abstract] | |
| Basis of presentation of financial statements | a. Basis of presentation of financial statements: These financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). |
| Basis of preparation of the interim consolidated financial statements | b. Basis of preparation of the interim consolidated financial statements: The interim condensed consolidated financial statements for the six and three months ended June 30, 2023 have been prepared in accordance with IAS 34 "Interim Financial Reporting". The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Company's annual financial statements as of December 31, 2022 that were included in the Annual Report on Form 20-F filed on March 16, 2023. The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Company’s annual consolidated financial statements for the year ended December 31, 2022 that were included in the Annual Report on Form 20-F filed on March 16, 2023. |
| General (Narrative) (Details) $ in Thousands | 1 Months Ended | 6 Months Ended | 12 Months Ended | |
| May 09, 2023 USD ($) Patient | Apr. 30, 2023 USD ($) | Jun. 30, 2023 USD ($) | Dec. 31, 2022 USD ($) | |
| BARDA | ||||
| Disclosure of associates [line items] | ||||
| Contract amount for research, development and manufacturing | $ 209,000 | |||
| Additional funding amount | $ 10,000 | |||
| U.S. Food and Drug Administration (FDA) [Member] | BARDA | ||||
| Disclosure of associates [line items] | ||||
| Contract amount for research, development and manufacturing | 7,000 | |||
| Replenishment amount | $ 3,000 | |||
| Number of patients | Patient | 50 | |||
| U.S. Department of Defense (DoD) [Member] | ||||
| Disclosure of associates [line items] | ||||
| Contracts with customers | $ 2,700 | $ 1,800 |
| Equity (Narrative) (Details) ₪ / shares in Units, $ / shares in Units, ₪ in Thousands, $ in Thousands | 1 Months Ended | 3 Months Ended | ||||||||
| Apr. 03, 2023 USD ($) Share $ / shares | Feb. 07, 2023 USD ($) $ / shares shares | May 31, 2023 USD ($) | Feb. 15, 2023 USD ($) Share $ / shares | Jun. 30, 2023 USD ($) | Jun. 30, 2022 USD ($) | Jun. 30, 2023 ₪ / shares shares | May 31, 2023 ILS (₪) ₪ / shares shares | Dec. 31, 2022 ₪ / shares shares | Jun. 30, 2022 ₪ / shares shares | |
| Disclosure of classes of share capital [line items] | ||||||||||
| Number of shares issued | shares | 7,252,234 | 12,857,143 | 7,240,020 | 4,734,774 | ||||||
| Ordinary shares, par value (per share) | ₪ / shares | ₪ 0.01 | ₪ 0.07 | ₪ 0.01 | ₪ 0.01 | ||||||
| Commissions and other offering expenses | $ 0 | $ 95 | ||||||||
| Authorized share capital | ₪ | ₪ 900,000 | |||||||||
| Increase Iin authorized share capital | ₪ | ₪ 1,400,000 | |||||||||
| Increase In shares issued | shares | 20,000,000 | |||||||||
| Increase in price per common shares issued | ₪ / shares | ₪ 0.07 | |||||||||
| Extension period for options exercised | 5 years | |||||||||
| Expenses recognized | $ 146 | |||||||||
| Public offering [Member] | ||||||||||
| Disclosure of classes of share capital [line items] | ||||||||||
| Number of shares issued | shares | 1,964,286 | |||||||||
| Ordinary shares, par value (per share) | $ / shares | $ 14 | |||||||||
| Proceeds from issuance of shares, net | $ 27,500 | |||||||||
| Commissions and other offering expenses | $ 2,031 | |||||||||
| Employees and officers [Member] | ||||||||||
| Disclosure of classes of share capital [line items] | ||||||||||
| Number of options granted | Share | 130,600 | |||||||||
| Exercise price per share | $ / shares | $ 13.32 | |||||||||
| Vesting period of share options | 4 years | |||||||||
| Total estimated value of stock option | $ 1,129 | |||||||||
| Employees and officers [Member] | Restricted Shares Units [Member] | ||||||||||
| Disclosure of classes of share capital [line items] | ||||||||||
| Number of restricted share units granted | Share | 9,100 | |||||||||
| Board members and officers [Member] | ||||||||||
| Disclosure of classes of share capital [line items] | ||||||||||
| Number of options granted | Share | 160,400 | |||||||||
| Vesting period of share options | 1-4 years | |||||||||
| Total estimated value of stock option | $ 884 | |||||||||
| Board members and officers [Member] | Minimum [Member] | ||||||||||
| Disclosure of classes of share capital [line items] | ||||||||||
| Exercise price per share | $ / shares | $ 11.89 | |||||||||
| Board members and officers [Member] | Maximum [Member] | ||||||||||
| Disclosure of classes of share capital [line items] | ||||||||||
| Exercise price per share | $ / shares | $ 11.91 | |||||||||
| 2014 Equity Incentive Plan [Member] | ||||||||||
| Disclosure of classes of share capital [line items] | ||||||||||
| Number of share available for issuance | shares | 1,000,000 | |||||||||
| Subsequent events (Narrative) (Details) - Subsequents Event [Member] - Biopharmax Group Ltd. [Member] $ in Thousands | Jul. 17, 2023 USD ($) ft² |
| Disclosure of non-adjusting events after reporting period [line items] | |
| Investment amount in property | $ 12,000 |
| Area of land | ft² | 32,500 |
| Rental expense | $ 625 |
| Increase in rent as percentage in every three years | 6% |
